.png)
Objective: Gonadotropin-releasing hormone analogs (GnRHa), such as leuprolide acetate (LA), are standard treatments for central precocious puberty (CPP). This study compared the effectiveness of the monthly 3.75 mg and 3-monthly 11.25 mg formulations in achieving puber tal suppression in girls with CPP.
Materials and Methods: This retrospective study included 136 girls with idiopathic CPP. Eighty six received LA 3.75 mg monthly, and 50 received LA 11.25 mg every 3 months for 1 year. Clinical, anthropometric, laboratory, and radiological parameters were evaluated at baseline and after 12 months. Pubertal suppression was defined as a peak luteinizing hormone (LH) level <4 IU/L after GnRH stimulation.
Results: Baseline characteristics were comparable between groups. After 12 months, no sig nificant differences were observed in bone age advancement, height SD Score (SDS), body mass index SDS, predicted adult height, or uterine volume. Pubertal suppression was achieved in 72.1% (3.75 mg) and 78% (11.25 mg) of patients (P = .291). Post-treatment LH and estradiol changes were similar between the 3.75 mg and 11.25 mg groups (median delta LH: −0.19 vs. −0.35 IU/L, P = .850; median delta estradiol: −21 vs. −13.9 pg/mL, P = .234), indicating compa rable hormonal responses to both formulations.
Conclusion: Both formulations demonstrated comparable effectiveness in pubertal suppres sion. The 3-monthly formulation, with similar safety and hormonal control, may improve adher ence and convenience due to reduced injection frequency. These findings support its use as an effective alternative for CPP management.
Cite this article as: Kilci F, Sarikaya E, Murat NÖ. Assessing pubertal suppression with 3.75 mg monthly versus 11.25 mg 3-monthly leuprolide acetate in girls with central precocious puberty. Turk Arch Pediatr. Published online December 31, 2025. doi:10.5152/TurkArchPediatr.2025.25186.